Plunkett Research Online: Resverlogix Corp

RESVERLOGIX CORP (RVXCF:PINX) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. .....



Resverlogix Corp
Ticker: RVXCF
Exchange: PINX
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 403 254-9252
Fax: 403 256-8495
Address: 4820 Richard Road South West
Suite 300
Calgary, AB T3E 6L1 Canada

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
Contacts Description
Donald McCaffreyCEO/Co-Founder/Director/President/Secretary/Chairman of the Board
A. CannCFO
See More
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. .....See More See More

Auditor: RSM Canada LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020202019
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: